Drug Updates

As a service to our members, HOPA provides information about newly approved oncology drugs. Using the Food and Drug Administration (FDA) as our source, we routinely aggregate and share drug updates to help keep you informed and up-to-date.

Whether you are early in your oncology pharmacy career, or you have been practicing for awhile, knowledge is power. Take a look at the drug listings below and their corresponding pages at fda.gov - and be sure to watch for HOPA's Friday FDA Alert email, too!

Please note: In providing his information for members, HOPA does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.

Pharmacist's Application to Practice (PAP)

HOPA's External Affairs Committee helps bring drug updates into focus by assigning, editing, and publishing a series of Pharmacist Applications to Practice, or PAPs.

PAP authors provide analysis and research on the application of these new drugs or indications and make their findings available as a resource for other members.

The Pharmacist Application to Practice page is currently under construction. Please check back soon for new PAPs.

Sort by:

Reset

Current as of: 05/04/2022
Encorafenib (BRAFTOVI, Array BioPharma Inc.)

FDA Information
Current as of: 05/04/2022
Ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.)

FDA Information
Current as of: 05/04/2022
Abatacept (ORENCIA, Bristol-Myers Squibb Company)

FDA Information
Current as of: 04/19/2023
polatuzumab vedotin-piiq (Polivy, Genentech, Inc.)

FDA Information
Current as of: 04/17/2023
omidubicel-onlv (Omisirge, Gamida Cell Ltd.)

FDA Information
Current as of: 04/03/2023
enfortumab vedotin-ejfv (Padcev, Astellas Pharma)

FDA Information
Current as of: 03/22/2023
retifanlimab-dlwr (Zynyz, Incyte Corporation)

FDA Information
Current as of: 03/16/2023
dabrafenib (Tafinlar, Novartis)

FDA Information
Current as of: 03/03/2023
abemaciclib (Verzenio,, Eli Lilly and Company)

FDA Information
Current as of: 02/09/2023
dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC)

FDA Information
Current as of: 02/03/2023
sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.)

FDA Information
Current as of: 01/27/2023
elacestrant (Orserdu, Stemline Therapeutics, Inc)

FDA Information
Current as of: 01/27/2023
pirtobrutinib (Jaypirca,, Eli Lilly and Company)

01/27/2023 Pharmacist's Application to Practice: Pirtobrutinib
Andy Hawn

FDA Information
Current as of: 01/26/2023
pembrolizumab (Keytruda, Merck)

FDA Information
Current as of: 01/19/2023
zanubrutinib (Brukinsa, BeiGene USA, Inc.)

FDA Information
Current as of: 01/19/2023
tucatinib (Tukysa, Seagen Inc.)

FDA Information
Current as of: 12/22/2022
mosunetuzumab-axgb (Lunsumio, Genentech, Inc)

FDA Information
Current as of: 12/16/2022
nadofaragene firadenovec-vncg (Adstiladrin, Ferring Pharmaceuticals)

FDA Information
Current as of: 12/14/2022
capecitabine (Xeloda, Genentech, Inc.)

FDA Information
Current as of: 12/12/2022
adagrasib (Krazati, Mirati Therapeutics, Inc)

FDA Information
Current as of: 12/09/2022
atezolizumab (Tecentriq, Genentech, Inc)

FDA Information
Current as of: 12/01/2022
olutasidenib (Rezlidhia, Forma Therapeutics, Inc.)

FDA Information
Current as of: 11/18/2022
asparaginase erwinia chrysanthemi (recombinant) (Rylaze, Jazz Pharmaceuticals)

FDA Information
Current as of: 11/14/2022
mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc)

FDA Information
Current as of: 11/10/2022
tremelimumab (Imjudo, AstraZeneca Pharmaceuticals)

11/10/2022 Pharmacist's Application to Practice: Tremelimumab
Rachel Vaught

FDA Information
Current as of: 11/10/2022
brentuximab vedotin (Adcetris, Seagen, Inc)

FDA Information
Current as of: 11/08/2022
cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc)

FDA Information
Current as of: 05/19/2023
epcoritamab-bysp (EPKINLY, Genmab US, Inc.)

FDA Information
Current as of: 05/31/2023
olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP)

FDA Information
Current as of: 06/15/2023
glofitamab-gxbm (COLUMVI, Genentech, Inc.)

FDA Information
Current as of: 07/31/2023
quizartinib (VANFLYTA, Daiichi Sankyo, Inc.)

FDA Information
Current as of: 07/31/2023
dostarlimab-gxly (JEMPERLI, GlaxoSmithKline)

FDA Information
Current as of: 08/02/2023
trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.)

FDA Information
Current as of: 08/09/2023
pralsetinib (GAVRETO, Genentech, Inc.)

FDA Information
Current as of: 09/21/2023
talquetamab-tgvs (TALVEY, Janssen Biotech, Inc.)

FDA Information
Current as of: 08/11/2023
niraparib and abiraterone acetate (AKEEGA, Janssen Biotech, Inc.)

FDA Information
Current as of: 09/14/2023
elranatamab-bcmm (ELREXFIO, Pfizer, Inc.)

FDA Information
Current as of: 09/14/2023
melphalan (HEPZATO, Delcath Systems, Inc.)

FDA Information
Current as of: 09/14/2023
temozolomide (TEMODAR, Merk)

FDA Information
Current as of: 06/20/2023
talazoparib (TALZENNA, Pfizer, Inc.)

FDA Information
Current as of: 11/10/2022
Tremelimumab (IMJUDO, AztraZeneca)

FDA Information
Current as of: 10/24/2022
Tremelimumab (IMJUDO, AztraZeneca)

FDA Information

Drug Updates

Pharmacist's Application to Practice (PAP)

Pharmacist's Applications to Practice

Pharmacist's Applications to Practice